literature supports the use of a dose ceiling of 10mg for both intravenous (IV) and intramuscular (IM) dosing. However, some practitioners prescribe needlessly excessive doses for pain control. The primary purpose of this study was to determine the current dosing patterns of ketorolac tromethamine, both for intravenous (IV) and intramuscular (IM) dosing, as well as to determine the amount of medication waste between ordered dose and vial size charged to the patients.
Study Objectives: Overutilization of hospital resources in low risk chest pain patients (LOWCPs) is a serious issue that has been addressed in multiple previous studies. It has been found that the implementation of accelerated diagnostic protocols for chest pain have shown substantial improvement in the utilization of health care resources. The development and subsequent validation of the history, electrocardiogram, age, risk factors, and troponin (HEART) score to identify ED chest pain patients who can safely be discharged without emergent provocative testing represents a potential breakthrough in the management of LOWCPs. Unfortunately, the gap between guideline development in academic centers and guideline adherence in community hospitals remains difficult to bridge. At our institution, multiple educational efforts to "get with the guidelines," including incorporating the HEART score into our electronic medical record, were attempted to assist in guideline adherence. Our study objective was to describe both the incidence and downstream effect of guideline non-adherence for LOWCPs placed in our community hospital observation unit with a HEART score < 4.
Methods: Between January 1, 2017 and March 31, 2017, we performed a retrospective observational study of all patients who were placed in the ED observation unit of our 100,000 visit/year community ED for evaluation of possible acute coronary syndrome. LOWCPs were included in the study after an initial negative ED work-up, including a normal or nonspecific electrocardiogram and negative initial cardiac biomarkers. Trained research associates utilizing a structured data extraction template collected patient information in order to calculate a HEART score for all patients who did not have one documented. Patients were stratified into two cohorts: 1) HEART score < 4 (LOW) and 2) HEART score >¼ 4 (HIGH). Our primary outcome measure was the incidence of guideline non-adherence, defined by LOWCPs in LOW transferred to the ED observation unit to undergo urgent provocative testing. Our secondary outcomes include the difference between HIGH and LOW for the following adverse events: 1) The incidence of "abnormal" provocative testing defined by the presence of at least "moderate" coronary stenosis, 2) The incidence of NSTEMI, and 3) 30-day ED return rate. Data were analyzed using descriptive statistics and the chisquare test for significance of categorical variables.
Results: A total of 149 patients (mean age 52.4 years, 56.4% female) met the inclusion criteria. 75 (50.34%) patients were in the LOW cohort, while 74 (49.66%) patients were in the HIGH cohort. Overall, 144 (96.64%) had stress testing and/or CT coronary angiography ordered during their observation stay. Of the patients with this additional testing, nine (6.12%) had "abnormal" results. One patient in the LOW cohort and eight patients in the HIGH cohort had "abnormal" results (p ¼ 0.0151). There was no difference in NSTEMI or 30-day ED return rates between the LOW and HIGH groups.
Conclusion: In our community hospital setting, guideline non-adherence with the HEART score resulted in twice the number of patients undergoing urgent provocative testing with a significantly lower proportion of those patients having "abnormal" findings.
Implementation of Federal Dependent Care

Policies for Physician Scientists at Top US Medical Schools
Ormseth C, Jagsi R, Lowenstein D, Hsia R/UCSF, San Francisco, CA; University of Michigan, Ann Arbor, MI Study Objectives: Measures to support physician scientists with dependent responsibilities can help address the sex gap in academic medicine. In 2014 the federal government issued regulation in 45 CFR 75.474 allowing temporary dependent care costs for required research-related travel to be expensed to federal grants. We investigated whether institutional policies at top-ranked U.S. medical schools allow for implementation of this clause.
Methods: We performed a cross-sectional survey of dependent care travel policies in 2019 at the top 51 U.S. medical schools through online searches. We identified and contacted administrators at each school to confirm accurate interpretation of policies.
Results: Of the 51 medical schools contacted, 48 provided details about institutional policies regarding dependent care. One school reported referring investigators to federal regulations for reimbursement of dependent care costs, though written policy was unavailable. Another school allows for reimbursement of such costs if both parents are required to travel or if the employee is a single parent. Four schools allow for reimbursement only for a bona fide business reason for the dependent to travel. Five schools reported allowing reimbursement of exceptional dependent care costs in the absence of an institutional policy. The remaining schools have policies that either classify dependent care as a non-reimbursable expense or do not reference dependent care. No school had a policy allowing for implementation of the dependent care clause as written in 45 CFR 75.474.
Conclusion: While the federal government issued regulation to allow for the reimbursement of temporary dependent care travel expenses for required researchrelated travel, currently few physician scientists can access this support because no medical schools have implemented the clause in institutional travel policy. Implementation of 45 CFR 75.474 at U.S. medical schools is an actionable step towards supporting physician scientists with dependents and achieving sex equality in academic medicine.
